MHRA: Meropenem PIL Defect Notification EL(26)A/39 Issued

• B. Braun Melsungen AG has issued an MHRA Class 4 defect notification EL(26)A/39 concerning errors in the Patient Information Leaflet (PIL) for Meropenem 1000 mg.
• The PIL errors involve incorrect sodium content in Section 2 and an inaccurate product strength statement in Section 6.
• Despite these informational discrepancies, the product's quality, efficacy, and the information on its label and Summary of Product Characteristics (SmPC) remain correct.
• The product is deemed critical for patients, so affected batches will continue to be supplied without repackaging to prevent supply disruption.
• Healthcare professionals should review the notification and can request updated PILs from B. Braun, while patients should continue their medication as prescribed.

Crucially, the quality of the physical product formulation and the efficacy of the medicinal product are entirely unaffected by these informational inaccuracies.

B. Braun Melsungen AG has issued a Class 4 medicines defect notification, EL(26)A/39, through the Medicines and Healthcare products Regulatory Agency (MHRA). This alert concerns a significant B. Braun Meropenem 1000 mg PIL error found in the Patient Information Leaflet (PIL) accompanying certain batches of Meropenem 1000 mg powder and solvent for solution for infusion.

The identified discrepancies relate specifically to the Meropenem Patient Information Leaflet sodium content and the stated strength of the product. Section 2 of the PIL contains incorrect information regarding the sodium content, while Section 6 inaccurately states the product's strength.

Despite these errors, the product itself remains critical for patients, a determination made following discussions between the MHRA and the Department of Health and Social Care. Consequently, all affected batches, including those not yet distributed, will continue to be supplied without repackaging to prevent supply disruption. All currently available stock contains the erroneous PIL.

The MHRA's notification clarifies that this Class 4 medicines defect UK is confined solely to the PIL. Crucially, the quality of the physical product formulation and the efficacy of the medicinal product are entirely unaffected by these informational inaccuracies. Furthermore, all information presented on the product label and within the Summary of Product Characteristics (SmPC) is correct and aligns with approved standards.

While Section 6 of the Patient Information Leaflet incorrectly references 500 mg, the correct 1000 mg strength is accurately displayed on the product packaging and in the relevant heading within the PIL itself. All other sections of the PIL are also free from error. This distinction is vital for maintaining pharmaceutical compliance UK, as the core regulatory documents and physical product remain sound.

Healthcare professionals are therefore explicitly advised to continue administering B. Braun Meropenem 1000 mg powder and solvent for solution for infusion in strict accordance with the approved Summary of Product Characteristics. The focus of the notification is on managing the informational discrepancy rather than any issue with the medication itself.

To address the B. Braun Meropenem 1000 mg PIL error, healthcare professionals are urged to thoroughly review the details contained within the MHRA Meropenem PIL defect notification EL(26)A/39. This review is particularly important when dispensing or administering the product, especially to new patients, to ensure accurate communication regarding the Meropenem Patient Information Leaflet sodium content and product strength.

B. Braun Melsungen AG has committed to providing hard copies of the updated PILs to wholesalers and pharmacies upon request. Entities wishing to obtain these corrected leaflets should contact medinfo.bbmuk@bbraun.com or call 08002980299, providing their address, product and batch details, and the required number of leaflets. This proactive measure supports pharmaceutical compliance UK by enabling the dissemination of accurate patient information.

Patients currently receiving this medication should continue their treatment as administered by their healthcare professional, as the quality of the solution for infusion is not compromised. Any patient concerns or questions should first be directed to their Outpatient Parenteral Antimicrobial Therapy (OPAT) team. Patients are cautioned against discontinuing their medication without consulting their treating healthcare professionals. Those experiencing adverse reactions or having questions about their medication should seek medical attention, and any suspected adverse reactions should be reported via the MHRA Yellow Card scheme. For medical information, contact medinfo.bbmuk@bbraun.com or 08002980299; for stock enquiries, email recalls.uk@bbraun.com or call 0114 2259155. Recipients of this Medicines and Healthcare products Regulatory Agency defect notification are responsible for bringing it to the attention of all relevant contacts.

Lawyers advising pharmaceutical distributors, pharmacies, or healthcare providers in the UK should alert clients to this MHRA notification. Clients must ensure staff are aware of the Meropenem PIL discrepancies and consider requesting updated leaflets from B. Braun to mitigate information-related compliance risks and ensure accurate patient communication, despite the product's continued use.

Source: Original reporting via the Medicines and Healthcare products Regulatory Agency